Gwenn Hansen
2021
In 2021, Gwenn Hansen earned a total compensation of $2.3M as Chief Scientific Officer at Nurix Therapeutics, a 48% increase compared to previous year.
Compensation breakdown
| Bonus | $97,600 |
|---|---|
| Non-Equity Incentive Plan | $186,180 |
| Option Awards | $1,579,597 |
| Salary | $433,750 |
| Other | $6,201 |
| Total | $2,303,328 |
Hansen received $1.6M in option awards, accounting for 69% of the total pay in 2021.
Hansen also received $97.6K in bonus, $186.2K in non-equity incentive plan, $433.8K in salary and $6.2K in other compensation.
Rankings
In 2021, Gwenn Hansen's compensation ranked 5,481st out of 12,406 executives tracked by ExecPay. In other words, Hansen earned more than 55.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,481 out of 12,406 | 56th |
Division Manufacturing | 2,315 out of 5,494 | 58th |
Major group Chemicals And Allied Products | 1,006 out of 2,369 | 58th |
Industry group Drugs | 896 out of 2,090 | 57th |
Industry Pharmaceutical Preparations | 645 out of 1,537 | 58th |
Source: SEC filing on March 25, 2022.
Hansen's colleagues
We found four more compensation records of executives who worked with Gwenn Hansen at Nurix Therapeutics in 2021.
News
Nurix Therapeutics CEO Arthur Sands' 2023 pay falls 54% to $4.4M
March 27, 2024
Nurix Therapeutics CEO Arthur Sands' 2022 pay jumps 97% to $9.4M
March 24, 2023
Nurix Therapeutics COO Stefani Wolff receives $7.1M in 2021
March 25, 2022
Nurix Therapeutics CEO Arthur Sands' 2020 pay jumps 1,041% to $17M
March 25, 2021